Risk factors of metabolic syndrome among adult Sudanese sickle cell anemia patients

AbstractBackgroundSickle cell disease is a hereditary disorder characterized by haematological anaemia. Several studies assumed that adult sickle patients might develop metabolic syndrome features as hyperglycaemia, hypertension and dyslipidaemia. The aim of this study was to evaluate the metabolic syndrome risk factors among adult Sudanese with sickle cell anemia in the steady state.MethodsA prospective cross sectional study design was conducted among thirty adult patients with sickle cell anemia Hb SS (mean age 23  ± 6.1 years) and thirty healthy individuals matched for age and gender. Waist and hip circumferences were measured by simple tape. Venous blood sample were analysed to detect blood glucose level, uric acid, total cholesterol, triglycerides, low and high-density lipoprotein after 8 h overnig ht fasting by spectrophotometer. Blood pressure was measured by sphygmomanometer. National Cholesterol Education Program-Adult Treatment Panel III was utilised to define metabolic syndrome. Statistical analysis was performed SPSS software version 23. Continuous data were expressed using mean ±  SD.P-value of
Source: BMC Hematology - Category: Hematology Source Type: research

Related Links:

ConclusionsPatients with CMS were more likely to present with increased comorbidities. Patients with CMS undergoing CABG were at risk for worse short ‐term secondary postoperative outcomes and reduced long‐term survival. The data supports the need for further investigation for risk reduction surrounding operative revascularization.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
Condition:   Anemia, Iron Deficiency Interventions:   Other: Nutritional Education;   Other: model nutrition kitchen;   Other: recipe book;   Other: Provision of Dates Sponsors:   National Research Center, Egypt;   Taibah University;   Rotary club of Heliopolis Sporting, Egypt;   Australian Embassy of Egypt;   Sustainable Development Project in the Kingdom of Saudi Arabia (KSA) Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Thromboembolic Pulmonary Hypertension Interventions:   Drug: Macitentan;   Drug: Placebo Sponsor:   Actelion Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   2019-nCoV Intervention:   Sponsor:   Chongqing Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Familial Hypercholesterolemia Intervention:   Sponsor:   Imperial College London Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
SummaryBackgroundPharmacological treatment options for adolescents with obesity are very limited. Glucagon ‐like‐peptide‐1 (GLP‐1) receptor agonist could be a treatment option for adolescent obesity.ObjectiveTo investigate the effect of exenatide extended release on body mass index (BMI) ‐SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity.MethodsSix ‐month, randomized, double‐blinded, parallel, placebo‐controlled clinical trial in patients (n = 44, 10‐18&thin...
Source: Pediatric Obesity - Category: Eating Disorders & Weight Management Authors: Tags: ORIGINAL RESEARCH Source Type: research
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Review Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
This study assessed treatment patterns and healthcare resource utilization (HRU) of patients with severe aplastic anemia (SAA) with insufficient response to immunosuppressive therapy (IST). A retrospective chart review was conducted at Dana-Farber Cancer Institute (DFCI), United States, and H ôpital Saint-Louis (HSL), France. Eligible patients were ≥ 18 years old, diagnosed with acquired SAA between January 1, 2006, and July 31, 2016, had insufficient response to IST, and had ≥ 12 months of follow-up post-diagnosis. Overall survival (OS) was estimated using the Kaplan-Meier method. Among the 40 patients, mean a...
Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractFanconi anemia (FA) is a DNA repair disorder resulting from mutations in genes encoding for FA DNA repair complex components and is characterized by variable congenital abnormalities, bone marrow failure (BMF), and high incidences of malignancies. FA mosaicism arises from reversion or other compensatory mutations in hematopoietic cells and may be associated with BMF reversal and decreased blood cell sensitivity to DNA-damaging agents (clastogens); this sensitivity is a phenotypic and diagnostic hallmark of FA. Uncertainty regarding the clinical significance of FA mosaicism persists; in some cases, patients have sur...
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Anemia | Cholesterol | Education | Hematology | Hypertension | Metabolic Syndrome | Sickle Cell Anemia | Statistics | Study | Sudan Health | Universities & Medical Training